CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues.

Yu, XB; Munoz-Sagredo, L; Streule, K; Muschong, P; Bayer, E; Walter, RJ; Gutjahr, JC; Greil, R; Conch, ML; Muller-Tidow, C; Hartmann, TN; Orian-Rousseau, V BLOOD. 2021; 138(12): 1067-1080.

Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.

Müller, M; Posch, F; Kiem, D; Barth, D; Horvath, L; Stotz, M; Schaberl-Moser, R; Pichler, M; Greil, R; Jost, PJ; Seeber, A; Amann, A; Schlick, K; Gerger, A; Riedl, JM; THER ADV MED ONCOL. 2021; 13: 17588359211039930

Casein Kinase 1D Encodes a Novel Drug Target in Hedgehog-GLI-Driven Cancers and Tumor-Initiating Cells Resistant to SMO Inhibition

Peer, E; Aichberger, SK; Vilotic, F; Gruber, W; Parigger, T; Grund-Groschke, S; Elmer, DP; Rathje, F; Ramspacher, A; Zaja, M; Michel, S; Hamm, S; Aberger, F CANCERS. 2021; 13(16): 4227

Response to Rituximab after Failure of Cyclophosphamide in the Induction Treatment in a Patient with cANCA-associated Vasculitis and Pachymeningitis: a Case Report

Psenak, O; Greil, R; Modern Rheumatology. 2021; 15(4): 68-71.

Dysphagia in the Context of a Serious Systemic Disease.

Ferstl, FS; Gampenrieder, SP; Renneberg, F; Roesch, S; Dysphagia. 2021; 36(3):497-499

Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?

Paar, V; Wernly, B; Zhou, Z; Motloch, LJ; Hoppe, UC; Egle, A; Lichtenauer, M; J Thromb Thrombolysis. 2021; 51(1):226-231

Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients

Schlick, K; Hohla, F; Hamacher, F; Hackl, H; Hufnagl, C; Markus, S; Magnes, T; Gampenrieder, SP; Melchardt, T; Stattner, S; Hauser-Kronberger, C; Greil, R; Rinnerthaler, G FUTUR SCI OA. 2021; 7(2): FSO644

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.

Wulf, GG; Altmann, B; Ziepert, M; DxxxAmore, F; Held, G; Greil, R; Tournilhac, O; Relander, T; Viardot, A; Wilhelm, M; Wilhelm, C; Pezzutto, A; Zijlstra, JM; Van Den Neste, E; Lugtenburg, PJ; Doorduijn, JK; van Gelder, M; van Imhoff, GW; Zettl, F; Braulke, F; Nickelsen, M; Glass, B; Rosenwald, A; Gaulard, P; Loeffler, M; Pfreundschuh, M; Schmitz, N; Trumper, L Leukemia. 2021; 35(1):143-155

Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in Austria.

Seeber, A; Weiss, L; Romeder, F; Szkandera, J; Kuehr, T; Kostner, S; Pichler, P; Jaeger, T; Kocher, F; Greil, R; Brodowicz, T Wien Klin Wochenschr. 2021; 133(1-2):21-25

Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).

Gillessen, S; Plütschow, A; Fuchs, M; Markova, J; Greil, R; Topp, MS; Meissner, J; Zijlstra, JM; Eichenauer, DA; Bröckelmann, PJ; Diehl, V; Borchmann, P; Engert, A; von Tresckow, B; Lancet Haematol. 2021; 8(4): e27-e288.